The company has been the quite achiever, this company now has around $5m cash in its coffers, has started a phase 1/11 human trial and has multiple opportunities for their unique strains-- which are showing significant anti inflammatory characteristics. The results of these trials will hopefully bring everyone's attention to us, and a re rate.
What they haven't been good at , is highlighting and convincing the market of what I believe is their significant potential-- at $40m M/C I believe they are just cheap and continue to add to my holdings. Which other company doing human trials is capitalised at under $100 to $150m-- I can't find one.
Cheers
NTI Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
